2019

• Drew, C. J. G.et al. 2019. A protocol for a randomised controlled, double-blind feasibility trial investigating fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, Learning and Memory in Epilepsy (FLAME trial). Pilot and Feasibility Studies (10.1186/s40814-019-0474-x)
• Drew, C. J. G.et al. 2019. A protocol for a randomised controlled, double-blind feasibility trial investigating fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, Learning and Memory in Epilepsy (FLAME trial). Pilot and Feasibility Studies 5(1), pp. -., article number: 87. (10.1186/s40814-019-0474-x)
• Drew, C. J. G.et al. 2019. Physical ACtivity and exercise outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month trial within cohort evaluation of a physical activity intervention in people with Huntington Disease. Physical Therapy, pp. -. (10.1093/ptj/pzz075)
• Morgan-Trimmer, S.et al. 2019. The acceptability of fluoride varnish and fissure sealant treatments in children aged 6-9 delivered in a school setting. Community Dental Health 36(1), pp. 33-38. (10.1922/CDH_4263Morgan-Trimmer06)

2017

• Chestnutt, I. G.et al. 2017. Fissure seal or fluoride varnish? A randomised trial of their relative effectiveness. Journal of Dental Research 96(7), pp. 754-761. (10.1177/0022034517702094)
• Busse-Morris, M.et al. 2017. Physical activity self-management and coaching compared to social interaction in Huntington’s disease: Results from the ENGAGE-HD randomized, controlled, pilot feasibility trial. Physical Therapy 97(6), pp. 625-639. (10.1093/ptj/pzx031)
• Chestnutt, I. G.et al. 2017. Seal or Varnish? A randomised controlled trial to determine the relative cost and effectiveness of pit and fissure sealant and fluoride varnish in preventing dental decay. Health Technology Assessment 21(21) (10.3310/hta21210)

2016

• Drew, C.et al. 2016. Integrating technology into complex intervention trial processes: a case study. Trials 17(1), article number: 551. (10.1186/s13063-016-1674-9)
• Jones, C.et al. 2016. The societal cost of Huntington’s disease: are we underestimating the burden?. European Journal of Neurology 23(10), pp. 1588-1590. (10.1111/ene.13107)
• Randell, E.et al. 2016. The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. Trials 17, pp. 398. (10.1186/s13063-016-1446-6)
• Fry, A. E.et al. 2016. Pathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy. BMC Medical Genetics 17, pp. -., article number: 34. (10.1186/s12881-016-0294-2)
• Quinn, L.et al. 2016. Development and delivery of a physical activity intervention for people with Huntington Disease. Journal of Neurologic Physical Therapy 40(2), pp. 71-80. (10.1097/NPT.0000000000000119)

2015

• Thomas, R. H.et al. 2015. Ethnicity can predict GLRA1 genotypes in hyperekplexia. Journal of Neurology, Neurosurgery & Psychiatry 86(3), pp. 341-343. (10.1136/jnnp-2014-307903)

2012

• Thompson, R., Drew, C. and Thomas, R. H. 2012. Next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges. Advances in Protein Chemistry and Structural Biology 89, pp. 27-63. (10.1016/B978-0-12-394287-6.00002-1)